Cargando…

UCB HCT in FLT3+ AML

Detalles Bibliográficos
Autores principales:	Ustun, Celalettin, Ruggeri, Annalisa, Weisdorf, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669843/ https://www.ncbi.nlm.nih.gov/pubmed/29137217 http://dx.doi.org/10.18632/oncotarget.21048

Ejemplares similares

OUTCOMES OF UCB TRANSPLANTATION ARE COMPARABLE IN FLT3+ AML: RESULTS OF CIBMTR, EUROCORD AND EBMT COLLABORATIVE ANALYSIS
por: Ustun, Celalettin, et al.
Publicado: (2017)

Age is no Barrier for Adults undergoing HCT for AML in CR1: Contemporary CIBMTR Analysis
por: Maakaron, Joseph E., et al.
Publicado: (2022)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
por: Cremer, Anjali, et al.
Publicado: (2023)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
por: Diral, Elisa, et al.
Publicado: (2023)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
por: Short, Nicholas J., et al.
Publicado: (2023)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

A Review of FLT3 Kinase Inhibitors in AML
por: Negotei, Cristina, et al.
Publicado: (2023)

Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?
por: Kim, Hee-Je
Publicado: (2010)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
por: Menghrajani, Kamal, et al.
Publicado: (2022)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Microenvironmental Hypoxia regulates FLT3 expression and biology in AML
por: Sironi, Silvia, et al.
Publicado: (2015)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Targeting FLT3 mutations in AML: review of current knowledge and evidence
por: Daver, Naval, et al.
Publicado: (2019)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
por: Loschi, Michael, et al.
Publicado: (2021)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
por: Maiorova, Varvara, et al.
Publicado: (2023)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
por: Engen, Caroline Benedicte Nitter, et al.
Publicado: (2014)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

Decisions in HCT and wine-making
por: McCann, Shaun
Publicado: (2020)

COVID-19, HCT and wine
por: McCann, Shaun R.
Publicado: (2020)

The effect of weather on HCT and vines
por: McCann, Shaun R.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e8kedmh8on2bve1ncmt70u2phf